Business
After years of contraction, investors see biotech reentering a growth cycle driven by scientific progress, asset quality and renewed conviction in oncology, obesity and neuroscience innovation.
FEATURED STORIES
With the biopharma industry performing better of late, analysts, executives and other industry watchers are “cautiously optimistic”—a term heard all over the streets of San Francisco at the J.P. Morgan Healthcare Conference earlier this month.
Attendance at the Biotech CEO Sisterhood’s annual photo of women leaders and allies in Union Square doubled this year. There’s still more work to do.
After winning a surprise approval for its hereditary angioedema drug Ekterly, KalVista is confident the oral offering will capture the lion’s share of the market for on-demand use.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
By using naturally-derived scaffolds, human cells and other biocompatible materials, 3D bioprinting has ushered in opportunities for researchers to design, print and optimize patient personalized tissues for purposes ranging from transplantation to drug testing.
Biopharma and life sciences companies bolster their leadership teams with these Movers & Shakers.
The pharma giant is currently the only manufacturer of the bladder cancer treatment for the U.S. and Europe.
This week, the judge overseeing her trial denied all efforts from her legal team to dismiss more than a dozen criminal charges against the Theranos founder.
Relief Therapeutics and NeuroRx released results on Tuesday from their open-label prospective study looking into RLF-100 (aviptadil) as a potential treatment for COVID-19 and respiratory failure.
To date, all the major clinical trials of vaccines against COVID-19 have been in adults.
Dyno will be responsible for the design of the novel AAV capsids that are expected to have improved functional properties for gene therapy. Roche and its subsidiary Spark Therapeutics will take the capsids and conduct preclinical studies with hopes of taking them into the clinic, and eventually to commercialization.
Takeda has entered into a five-year agreement with Accenture and Amazon Web Services (AWS) to support the Tokyo-based pharmaceutical company in moving 80% of its applications to the “cloud” and modernizing the company’s research tools.
The urgency of 2020 has shone a spotlight on the investment and advances in the U.S. biotech industry over the past decade – and overall, it is looking strong.
Femtech represents significant growth opportunities for biotech companies, but is still under the radar for most investors. None-the-less, pioneering companies are emerging to address this sector’s many underserved needs.